Viewing Study NCT00004842



Ignite Creation Date: 2024-05-05 @ 11:07 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004842
Status: COMPLETED
Last Update Posted: 2017-05-31
First Post: 2000-02-24

Brief Title: Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK

Study Overview

Official Title: Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis
Status: COMPLETED
Status Verified Date: 2017-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Assess the safety and effectiveness of budesonide in patients with primary sclerosing cholangitis or primary biliary cirrhosis experiencing a suboptimal response to ursodeoxycholic acid

II Estimate the efficacy of this therapy in these patient groups as a means of evaluating the feasibility of a long-term randomized trial
Detailed Description: PROTOCOL OUTLINE

Patients receive budesonide by mouth 3 times daily for a minimum of 6 months If liver biochemistries become normal dosage is reduced to once daily Treatment discontinues after 1 year

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
MAYOC-41296 OTHER None None
R03DK052344 NIH Mayo Clinic httpsreporternihgovquickSearchR03DK052344